Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Ultragenyx Pharmaceutical (RARE) Could Be 42% Undervalued On EMA Filing Progress

3 October 2026 · By · Wire by Fusion42

Published

3 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at simplywall.st →

◆ Verified

Fusion42 · 3 October 2026 · Fusion42 review

Ultragenyx Pharmaceutical's gene therapy for Sanfilippo syndrome Type A has progressed with EMA validation following FDA approval, yet its shares remain significantly undervalued by about 42% against analyst targets amid concerns over commercialization risks and sustained losses.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Ultragenyx’s EMA validation creates a narrow window to capitalise on its undervaluation before gene therapy execution risks surface. If you invest now, you can leverage this rare approval milestone ahead of competitors re-pricing risk around losses and commercial strain.

◆ Coverage

1 source · 3 Oct 2026

◆ Related on Wire

◆ Topics

Biotechgene-therapyema-approvalvaluation-gapbiotech-riskinvestment-opportunity